Arthritis/rheumatic disorders:
Indications for: NALFON
Rheumatoid arthritis. Osteoarthritis.
Adult Dosage:
Use lowest effective dose for shortest duration. 400mg–600mg 3 or 4 times daily. Max: 3.2g/day.
Children Dosage:
<18yrs: not established.
NALFON Contraindications:
Aspirin allergy. Coronary artery bypass graft surgery.
Boxed Warning:
Risk of serious cardiovascular and gastrointestinal events.
NALFON Warnings/Precautions:
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Hearing impaired. Elderly. Debilitated. Labor & delivery. Pregnancy (3rd trimester; avoid). Nursing mothers.
NALFON Classification:
NSAID (arylacetic acid deriv.).
NALFON Interactions:
Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors (eg, captopril), ARBs (eg, losartan), or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. May be antagonized by phenobarbital. May potentiate protein-bound drugs (eg, hydantoins, sulfonamides, sulfonylureas).
Adverse Reactions:
Dyspepsia, headache, somnolence, nausea, dizziness, constipation, nervousness, asthenia, peripheral edema; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypertension, hypersensitivity reactions, anemia/blood dyscrasias.
How Supplied:
Caps 200mg—100; 400mg—90, 500
Nonnarcotic analgesics:
Indications for: NALFON
Mild to moderate pain.
Adult Dosage:
Use lowest effective dose for shortest duration. 200mg every 4–6hrs as needed.
Children Dosage:
<18yrs: not established.
NALFON Contraindications:
Aspirin allergy. Coronary artery bypass graft surgery.
Boxed Warning:
Risk of serious cardiovascular and gastrointestinal events.
NALFON Warnings/Precautions:
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Hearing impaired. Elderly. Debilitated. Labor & delivery. Pregnancy (3rd trimester; avoid). Nursing mothers.
NALFON Classification:
NSAID (arylacetic acid deriv.).
NALFON Interactions:
Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors (eg, captopril), ARBs (eg, losartan), or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. May be antagonized by phenobarbital. May potentiate protein-bound drugs (eg, hydantoins, sulfonamides, sulfonylureas).
Adverse Reactions:
Dyspepsia, headache, somnolence, nausea, dizziness, constipation, nervousness, asthenia, peripheral edema; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypertension, hypersensitivity reactions, anemia/blood dyscrasias.
How Supplied:
Caps 200mg—100; 400mg—90, 500
